Blood
Articles in this Issue
Silibinin enhances daunorubicin chemosensitivity in Acute Myeloid Leukemia by suppressing PDIA3-mediated autophagy
Abstract Background Acute myeloid leukemia (AML) presents significant therapeutic challenges, particularly due to the resistance to chemothe...
Retention of immunosuppressive C1Q macrophages following therapeutic interventions imparts negative outcomes across human multiple myeloma studies
Abstract Overview: The emergence of effective immune therapies for multiple myeloma has highlighted the importance of understanding the role...
Serum mirnas predict response to CAR-T cell therapy in large B-cell lymphoma
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of relapsed or refractory diffuse lar...
DHODH-driven pyrimidine metabolism is a targetable vulnerability in myeloproliferative neoplasms
Abstract Metabolic rewiring is a hallmark of malignancy, enabling cancer cells to sustain proliferation and resist apoptosis. The extent to...
Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia
Abstract Introduction: Mutations (mut) in CEBPA occur in 7-20% of patients (pts) with de novo acute myeloid leukemia (AML). In-frame mut in...
Efficacy and safety analysis of iptacopan in paroxysmal nocturnal hemoglobinuria: A real world retrospective study of China
Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disorder of hematopoietic stem cells (HSCs), charac...
Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors
Abstract Introduction: With the success of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML), since 2005...
Exploiting arginine auxotrophy in Philadelphia-chromosome positive acute lymphoblastic leukemia to deliver personalised metabolomic treatment
Abstract Background Asparagine depletion with asparaginase exemplifies the successful therapeutic exploitation of metabolic dependencies in...
Synergistic Remission of refractory cutaneous T-cell lymphoma by linperlisib plus venetoclax via targeting the PI3K/AKT/CREB-BCL-2/MCL-1 signaling axis.
Abstract Background: Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of lymphoproliferative malignancies arising from skin-homing...
CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission
Abstract Introduction: Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have dismal outcomes due to adverse-risk disease biolog...
PARP1 facilitates transcriptional activity and stability of the BCL6 protein and is a therapeutic target in BCL6 expressing lymphomas
Abstract BCL6, the “master regulator” of the Germinal Center (GC) reaction, is a transcriptional repressor implicated in lymphomagenesis. De...
Rapid decrease in age-adjusted mortality rates associated with ITP following eltrombopag aand romiplostin approvals, but not in TMA following eculizumab approval, 1999-2023
Abstract Introduction: Idiopathic Thrombocytopenic Purpura (ITP), Thrombotic Microangiopathy (TMA) and Disseminated Intravascular Coagulatio...
Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation
Abstract Introduction Short diagnosis-to-treatment interval (DTI) is associated with aggressive disease biology and inferior outcomes in diff...
Optimizing fludarabine: The impact of fludarabine renal dose adjustment during lymphodepletion prior to CAR-T cell immunotherapy in multiple myeloma patients
Abstract Background: Fludarabine and cyclophosphamide is a standard-of-care lymphodepletion regimen for chimeric antigen receptor (CAR) T-ce...
Balancing efficacy and safety: IL-15 BCMA CAR-T cells vs. 2nd generation CAR-T in preclinical myeloma model
Abstract Multiple myeloma (MM) is the second most frequent hematologic malignancy worldwide and remains incurable. Current treatments are co...
Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia
Abstract Background: The overall survival for pediatric/young adult acute myeloid leukemia (AML) approaches 70% with current therapies. In c...
Patient-reported outcomes and quality of life over time in relapsed/refractory diffuse B-cell lymphoma (DLBCL) patients treated with CAR T-cells therapy in clinical practice
Abstract Background In the context of potential lymphoma curability with the improvement of life expectancy after CAR T-cells, the question...
Targeting nicotinamide salvage pathway is a unique metabolic vulnerability of high-risk MDS stem cells
Abstract Background: High-risk myelodysplastic syndrome (MDS) is an incurable age-related clonal disorder of the hematopoietic stem cell (HS...
Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.
Abstract Introduction Despite advances in Hodgkin lymphoma (HL) treatment, effective strategies for relapsed/refractory (R/R) HL, especially...
Single-cell dissection of CAR-T and blinatumomab-elicited T cell states uncovers therapy-specific functional decay patterns
Abstract Introduction Chimeric antigen receptor T-cells targeting CD19 (CD19 CAR-T) and blinatumomab represent two leading immunotherapeutic...
Comprehensive analysis of early ctdna kinetics following first cycle of R-CHOP in LBCL patients
Abstract IntroductionCirculating tumor DNA (ctDNA) has become a well-established dynamic biomarker in Large B Cell Lymphoma (LBCL). Previous...
Donor-derived sars-cov-2-specific T cells to prevent COVID-19 early post allogeneic hematopoietic stem cell transplant
Abstract Background: Despite the availability of effective vaccines, post-allogeneic hematopoietic stem cell transplant (HSCT) patients are...
BCMA-targeted CAR-NK cell therapy using lipid nanoparticle mRNA delivery for multiple myeloma
Abstract Multiple myeloma (MM) is the second most common hematologic malignancy (Mikhael et al. Am J Med 2023). Despite advances in treatmen...
Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia
Abstract Purpose: Gilteritinib plus venetoclax and azacitidine (GVA) therapy has achieved promising efficacy in older/unfit patients with FL...
CD8+hla-DR+CD27+ t cells define a population of naturally occurring regulatory precursors in humans
Abstract The biology of CD8 regulatory T cells (Tregs) under steady-state conditions remains poorly understood due to their phenotypic heter...